Redwood Investment Management LLC Invests $394,000 in Abbott Laboratories $ABT

Redwood Investment Management LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 1st quarter, Holdings Channel reports. The fund purchased 2,972 shares of the healthcare product maker’s stock, valued at approximately $394,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock valued at $17,274,000 after acquiring an additional 2,774 shares during the last quarter. Voleon Capital Management LP bought a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $273,000. Rehmann Capital Advisory Group raised its holdings in shares of Abbott Laboratories by 2.6% during the fourth quarter. Rehmann Capital Advisory Group now owns 11,753 shares of the healthcare product maker’s stock valued at $1,329,000 after purchasing an additional 298 shares during the last quarter. Finally, Parvin Asset Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $963,000. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on ABT. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Finally, Morgan Stanley raised their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $144.47.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $131.39 on Thursday. The stock has a market cap of $228.68 billion, a PE ratio of 16.47, a price-to-earnings-growth ratio of 2.50 and a beta of 0.70. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The firm has a fifty day moving average price of $131.01 and a 200-day moving average price of $131.33. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the previous year, the company earned $1.14 EPS. Abbott Laboratories’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were given a dividend of $0.59 per share. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.